Researchers at UC Santa Cruz have found patterns in RNA sequencing data that have led to possible treatments for cancers with no actionable mutations.
Genapsys plans to launch the portable instrument in the second half of this year, and has signed on several early-access customers.
The findings implicated immune response, lipid metabolism, tau binding proteins, and amyloid precursor protein metabolism pathways in disease risk.
Researchers defined six malignant cell clusters with single-cell transcriptomes and genotypes for thousands of acute myeloid leukemia cells.
The company also reported higher operating costs due to an expansion of its US sales force, as well as its European commercial and laboratory staff.
The firm plans to submit its Idylla MSI test for 510(k) clearance from the US Food and Drug Administration after receiving CE-IVD approval this morning.
Centogene said it will conduct molecular diagnostic testing using deletion/duplication analysis and full-length sequencing of the DMD gene.
At the AGBT meeting last night, Johns Hopkins researcher Joshua Cohen said that the partners are looking to recruit 50,000 healthy individuals for the study.
Agilent has launched the Magnis NGS Prep System, a fully automated next-generation sequencing library preparation system. The firm has designed the platform to help researchers easily assay multiple genes and complex genetic aberrations from genomic DNA, including degraded samples such as formalin-fixed, paraffin-embedded specimens, Agilent said. The system comes with pre-aliquoted reagents and pre-set protocols, and is fully compatible with Agilent's SureSelect [XT HS] library prep workflow. The system can provide reproducible results with a one-day turnaround time, Agilent noted.
Data being presented at the upcoming AACR meeting show that Guardant's liquid biopsy test provided more accurate and rapid mutation detection than tissue genotyping.
The firms are focusing on developing a rapid diagnostic test for African swine fever that can be used on GNA's portable MDx platform.
The assay monitors mutations across a patient's genome and matches them to mutations found in a patient's resected tumor and in DNA in the bloodstream.
The firm said that its cell-free DNA assay has shown a high positive predictive value in preliminary clinical studies involving stage IV colorectal cancer patients.
The test uses qPCR to measure the methylation level of three bladder cancer-specific biomarkers in patient urine samples.
The firm also reported full-year 2018 sales of €2.42 billion, a year-over-year increase of 6 percent on a reported basis, or 10 percent organically.
Biocept will use its liquid biopsy assay to test cerebrospinal fluids of patients diagnosed with certain cancers and then compare results to standard methods.